Research Article

Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results

Table 1

Patients’ characteristics at enrollment.

SLE ()HSs ()

Age (years)39 (35–46.25)40.5 (35–46.5)ns
Sex (F/M)29/129/1ns
Disease duration (months)64 (31–99)NA
Antiphospholipid syndrome (N)900.0019
Anti-dsDNA positivity (N)180<0.0001
Hypcomplementemia C3 (N)190<0.0001
C3 (g/l)0.69 (0.34–0.8)1.01 (0.96–1.2)0.0002
Hypocomplementemia C4 (N)1000.0008
C4 (g/l)0.078 (0.03–0.115)0.15 (0.1–0.225)0.0039
No prednisone (N)430<0.0001
Prednisone ≤5 mg (N)1300.0003
Prednisone >5 mg1300.0003
Immunosuppressants (N)18NA
Hydroxychloroquine (N)19NA
Low dose aspirin (N)800.0046
SELENA-SLEDAI4 (2–6.75)NA
BILAG A4NA
BILAG B9NA
SDI0.917 (0–1.04)NA

NA: not applicable; ns: not significant.